• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

小细胞肺癌患者的复发模式——胸部放疗和预防性颅脑放疗联合强化化疗对长期生存的影响

[Patterns of relapse in patients with small cell lung cancer--the effect of chest irradiation and prophylactic cranial irradiation combined with intensive chemotherapy on long-term survival].

作者信息

Ueoka H, Ohnoshi T, Numata T, Kawahara S, Nishii K, Yonei T, Yamashita H, Moritaka T, Kiura K, Uji H

机构信息

Department of Medicine, Okayama University Medical School.

出版信息

Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Dec;28(12):1581-7.

PMID:1963910
Abstract

The pattern of relapse was analyzed in patients with small cell lung cancer (SCLC). Of 180 patients treated with intensive combination chemotherapy between 1976 and 1987, 75 achieved complete response (CR). Of 47 patients with limited disease (LD), 20 (43%) initially relapsed in the chest and 7 (15%) in the brain. Among 27 patients with extensive disease (ED), the chest was also the most frequent site of relapse (44%) followed by the brain (19%). In LD patients who had received chemotherapy plus chest irradiation, the initial relapse rate and the cumulative relapse rate in the chest at 2 years were only 29% and 35.4%, respectively. These rates were significantly lower compared with the rates of 69% and 76.5% for patients who had received chemotherapy alone (p less than 0.05). Survival was improved to some extent by the addition of chest irradiation, but not significantly, however, the long-term survival rate favored those receiving chest irradiation. Prophylactic cranial irradiation (PCI) reduced the frequency of brain relapse and significantly improved the survival of SCLC patients achieving CR. The median survival time and 5-year survival rate of patients who received PCI were 23.1 months and 26.7%, which these figures were only 14.0 months and 8.3% for those who had not respectively. Analysis using Cox's proportional hazard model showed that PCI was the greatest prognostic factor favoring the SCLC patients achieving CR. These results indicate that chest irradiation and PCI in conjunction with intensive combination chemotherapy are effective for cases of SCLC with CR.

摘要

对小细胞肺癌(SCLC)患者的复发模式进行了分析。在1976年至1987年间接受强化联合化疗的180例患者中,75例获得完全缓解(CR)。在47例局限性疾病(LD)患者中,20例(43%)最初在胸部复发,7例(15%)在脑部复发。在27例广泛性疾病(ED)患者中,胸部也是最常见的复发部位(44%),其次是脑部(19%)。在接受化疗加胸部放疗的LD患者中,2年时的初始复发率和胸部累积复发率分别仅为29%和35.4%。与仅接受化疗的患者的69%和76.5%相比,这些比率显著更低(p<0.05)。胸部放疗在一定程度上改善了生存率,但不显著,然而,长期生存率有利于接受胸部放疗的患者。预防性颅脑照射(PCI)降低了脑部复发的频率,并显著改善了达到CR的SCLC患者的生存率。接受PCI的患者的中位生存时间和5年生存率分别为23.1个月和26.7%,而未接受PCI的患者分别仅为14.0个月和8.3%。使用Cox比例风险模型进行的分析表明,PCI是有利于达到CR的SCLC患者的最大预后因素。这些结果表明,胸部放疗和PCI联合强化联合化疗对达到CR的SCLC病例有效。

相似文献

1
[Patterns of relapse in patients with small cell lung cancer--the effect of chest irradiation and prophylactic cranial irradiation combined with intensive chemotherapy on long-term survival].小细胞肺癌患者的复发模式——胸部放疗和预防性颅脑放疗联合强化化疗对长期生存的影响
Nihon Kyobu Shikkan Gakkai Zasshi. 1990 Dec;28(12):1581-7.
2
Decreased metastasis and improved survival with early thoracic radiotherapy and prophylactic cranial irradiation in combined-modality treatment of limited-stage small cell lung cancer.在局限期小细胞肺癌的综合治疗中,早期胸部放疗和预防性颅脑照射可减少转移并提高生存率。
Radiat Oncol Investig. 1998;6(5):226-32. doi: 10.1002/(SICI)1520-6823(1998)6:5<226::AID-ROI4>3.0.CO;2-H.
3
[Small cell lung cancer: a retrospective analysis of results of chemotherapy and combined modality treatment].[小细胞肺癌:化疗及综合治疗结果的回顾性分析]
Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 2-2):1341-8.
4
Chemotherapy for small cell lung carcinoma: the Greenlane Hospital experience 1993-1995.小细胞肺癌的化疗:格林莱恩医院1993 - 1995年的经验
N Z Med J. 1998 Nov 27;111(1078):451-2, 453-4.
5
Prognostic factors in limited-stage small cell lung cancer of patients treated with combined modality approach.采用综合治疗方法治疗的局限期小细胞肺癌患者的预后因素。
J BUON. 2006 Jan-Mar;11(1):31-7.
6
Evaluation of the use of prophylactic cranial irradiation in small cell lung cancer.小细胞肺癌预防性颅脑照射应用的评估
Cancer. 2009 Feb 15;115(4):842-50. doi: 10.1002/cncr.24105.
7
Prophylactic cranial irradiation in limited-stage small-cell lung cancer: a retrospective analysis.局限期小细胞肺癌的预防性颅脑照射:一项回顾性分析
Clin Adv Hematol Oncol. 2004 Jun;2(6):397-400.
8
Concurrent cisplatin-etoposide chemotherapy plus thoracic radiotherapy for limited-stage small cell lung cancer. Japanese Lung Cancer Chemotherapy Group in Japanese Clinical Oncology Group.顺铂联合依托泊苷化疗同步胸部放疗治疗局限期小细胞肺癌。日本肺癌化疗组(日本临床肿瘤学会)
Jpn J Clin Oncol. 1994 Oct;24(5):275-81.
9
Cisplatin and etoposide alternating ifosfamide, vincristine, epirubicin in small cell lung cancer.顺铂和依托泊苷交替联合异环磷酰胺、长春新碱、表柔比星治疗小细胞肺癌。
Saudi Med J. 2003 Jun;24(6):628-31.
10
Experience of a German multicenter study group with ifosfamide in small cell lung cancer.德国多中心研究小组使用异环磷酰胺治疗小细胞肺癌的经验。
Semin Oncol. 1989 Feb;16(1 Suppl 3):9-18.